FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
1. FDA approves Merck's Enflonsia for RSV protection in infants. 2. Product to launch before upcoming RSV season in fall. 3. Sales potential against competitor Beyfortus, which faced supply issues. 4. Enflonsia showed over 84% hospitalization reduction in trials. 5. Approval expands treatment options for a serious infant illness.